SCHEDULE 13G/A: Barclays PLC Updates Significant Stake in Surmodics Inc, Holding 7.26% of Common Stock
Beneficial Ownership Report
Barclays PLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.26% of Surmodics Inc's common stock, totaling 1,039,058 shares as of December 31, 2024.
Summary
- Barclays PLC, a United Kingdom-based entity, has filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Surmodics Inc.
- As of December 31, 2024, Barclays PLC beneficially owns 1,039,058 shares of Surmodics Inc's common stock.
- This ownership represents 7.26% of the total class of Surmodics Inc's common stock.
- Barclays PLC holds sole voting power and sole dispositive power over all 1,039,058 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Surmodics Inc.
- Subsidiaries identified as acquiring the security include Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, inherently neutral in sentiment regarding the issuer's performance, though the presence of a large institutional investor can be perceived positively by the market.
Positives
- The disclosure of a significant stake (7.26%) by a major global financial institution like Barclays PLC could be interpreted by the market as a vote of confidence in Surmodics Inc.
Negatives
- This Schedule 13G filing does not contain information that would be categorized as negatives regarding Surmodics Inc's operational or financial performance.
Risks
- This Schedule 13G filing does not contain information regarding current issues or potential future challenges related to Surmodics Inc's business operations or financial health.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Surmodics Inc's future performance or outlook.
Industry Context
This filing is a standard disclosure of a significant passive investment by a financial institution in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially share price, signaling institutional confidence.
- Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the holding is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which required the filing of this statement, indicating the beneficial ownership position. |
| 03/21/2025 | Date the Schedule 13G Amendment No. 1 was signed by Barclays PLC. |
Keywords
Barclays PLC, Surmodics Inc, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.